- post-bariatric hypoglycemia (PBH) is a rare but serious complication that can occur after bariatric surgery, especially Roux-en-Y gastric bypass It is characterized by recurrent episodes of low blood glucose levels and is typically triggered by high-carbohydrate meals
- The demand for PBH treatment is increasing due to the rise in obesity treatment through bariatric surgery, growing recognition of PBH among healthcare professionals, and the availability of novel therapeutic options such as gLp-1 receptor agonists and alpha-glucosidase inhibitors
- North America is expected to dominate the post-bariatric hypoglycemia (PBH) treatment market with a share of 38 9%, due to a high volume of bariatric procedures, well-established healthcare systems, and early adoption of new therapies
- Asia-pacific is expected to be the fastest growing region in the post-bariatric hypoglycemia (PBH) treatment market during the forecast period due to rising obesity rates, increasing medical tourism for bariatric surgery, and improved diagnostic awareness of PBH
- Alpha-glucosidase inhibitors are anticipated to dominate the market with a market share of 33 2%, owing to their effectiveness in slowing carbohydrate absorption, thereby preventing postprandial glucose spikes and subsequent hypoglycemia Despite emerging options, alpha-glucosidase inhibitors remain widely used due to their clinical efficacy, low cost, and tolerability profile Their familiarity among clinicians and suitability for long-term use contributes to their market leadership
